SEARCH

SEARCH BY CITATION

References

  • 1
    Feldman EC, Nelson RW. Canine and Feline Endocrinology and Reproduction, 3rd ed. St. Louis, MO:Saunders Elsevier; 2004:86151.
  • 2
    Barber LG. Thyroid tumors in dogs and cats. Vet Clin North Am Small Anim Pract 2007;37:755773, vii.
  • 3
    van Hoek I, Peremans K, Waelbers T, et al. Non-surgical treatment of feline hyperthyroidism: Options and considerations. Vlaams Diergeneeskundig Tijdschrift 2007;76:6980.
  • 4
    Colzani RM, Alex S, Fang SL, et al. The effect of recombinant human thyrotropin (rhTSH) on thyroid function in mice and rats. Thyroid 1998;8:797801.
  • 5
    Thotakura NR, Desai RK, Szkudlinski MW, et al. The role of the oligosaccharide chains of thyrotropin alpha- and beta-subunits in hormone action. Endocrinology 1992;131:8288.
  • 6
    Rayalam S, Eizenstat LD, Hoenig A, et al. Cloning and sequencing of feline thyrotropin (fTSH): Heterodimeric and yoked constructs. Domest Anim Endocrinol 2006;30:203217.
  • 7
    Greco DS, Stabenfeldt GH. Endocrinology. In: Cunningham JG, Klein BG, eds. Textbook of Veterinary Physiology, 4th ed. St. Louis, MO: Saunders Elsevier; 2007:428464.
  • 8
    Ekholm R, Engstrom G, Ericson LE, et al. Exocytosis of protein into the thyroid follicle lumen: An early effect of TSH. Endocrinology 1975;97:337346.
  • 9
    Kogai T, Endo T, Saito T, et al. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 1997;138:22272232.
  • 10
    Nilsson M, Engstrom G, Ericson LE. Graded response in the individual thyroid follicle cell to increasing doses of TSH. Mol Cell Endocrinol 1986;44:165169.
  • 11
    Verschueren CP, Rutteman GR, Vos JH, et al. Thyrotrophin receptors in normal and neoplastic (primary and metastatic) canine thyroid tissue. J Endocrinol 1992;132:461468.
  • 12
    Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010;20:135146.
  • 13
    Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:12291242.
  • 14
    McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34:554564.
  • 15
    Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:43184323.
  • 16
    Sipos JA, Mazzaferi EL. Differentiated thyroid carcinoma. In: Cooper DS, ed. Medical Management of Thyroid Disease, 2nd ed. New York: Informa Healthcare; 2008:237295.
  • 17
    Hays MT, Solomon DH, Beall GN. Suppression of human thyroid function by antibodies to bovine thyrotropin. J Clin Endocrinol Metab 1967;27:15401549.
  • 18
    Kirkpatrick CH, Meek JC, Rich RR. Mechanism of allergy to components of commercial bovine thyrotropin. J Allergy Clin Immunol 1973;51:296302.
  • 19
    Krishnamurthy GT. Human reaction to bovine TSH: Concise communication. J Nucl Med 1978;19:284286.
  • 20
    Melmed S, Harada A, Hershman JM, et al. Neutralizing antibodies to bovine thyrotropin in immunized patients with thyroid cancer. J Clin Endocrinol Metab 1980;51:358363.
  • 21
    Brown P, Gajdusek DC, Gibbs CJ Jr, et al. Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med 1985;313:728731.
  • 22
    Law A, Jack GW, Tellez M, et al. In-vivo studies of a human-thyrotrophin preparation. J Endocrinol 1986;110:375378.
  • 23
    Hayashizaki Y, Miyai K, Kato K, et al. Molecular cloning of the human thyrotropin-beta subunit gene. FEBS Lett 1985;188:394400.
  • 24
    Thotakura NR, Desai RK, Bates LG, et al. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 1991;128:341348.
  • 25
    Watanabe S, Hayashizaki Y, Endo Y, et al. Production of human thyroid-stimulating hormone in Chinese hamster ovary cells. Biochem Biophys Res Commun 1987;149:11491155.
  • 26
    Kashiwai T, Ichihara K, Endo Y, et al. Immunological and biological characteristics of recombinant human thyrotropin. J Immunol Methods 1991;143:2530.
  • 27
    Pacini F, Castagna MG. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008;22:10091021.
  • 28
    Pacini F, Schlumberger M, Harmer C, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: A consensus report. Eur J Endocrinol 2005;153:651659.
  • 29
    Duntas LH, Biondi B. Short-term hypothyroidism after levothyroxine-withdrawal in patients with differentiated thyroid cancer: Clinical and quality of life consequences. Eur J Endocrinol 2007;156:1319.
  • 30
    Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878884.
  • 31
    Berg G, Lindstedt G, Suurkula M, et al. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002;25:4452.
  • 32
    Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: A single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 2003;30:10771086.
  • 33
    Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001;11:865869.
  • 34
    Elisei R, Schlumberger M, Driedger A, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 2009;94:41714179.
  • 35
    Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926932.
  • 36
    Rosario PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 2008;49:17761782.
  • 37
    Robbins RJ, Driedger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 2006;16:11211130.
  • 38
    Tala H, Robbins R, Fagin JA, et al. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab 2011;96:21052111.
  • 39
    Ceccarelli C, Antonangeli L, Brozzi F, et al. Radioiodine (131)I treatment for large nodular goiter: Recombinant human thyrotropin allows the reduction of radioiodine (131)I activity to be administered in patients with low uptake. Thyroid 2011;21:759764.
  • 40
    Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr Pract 2003;9:204209.
  • 41
    Duick DS, Baskin HJ. Significance of radioiodine uptake at 72 hours versus 24 hours after pretreatment with recombinant human thyrotropin for enhancement of radioiodine therapy in patients with symptomatic nontoxic or toxic multinodular goiter. Endocr Pract 2004;10:253260.
  • 42
    Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000;85:35923596.
  • 43
    Nieuwlaat WA, Hermus AR, Ross HA, et al. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone. J Nucl Med 2004;45:626633.
  • 44
    Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, et al. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 2001;86:53305336.
  • 45
    Nieuwlaat WA, Huysmans DA, van den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003;88:31213129.
  • 46
    Boretti FS, Breyer-Haube I, Kaspers B, et al. Clinical, hematological, biochemical and endocrinological aspects of 32 dogs with hypothyroidism. Schweiz Arch Tierheilkd 2003;145:149156, 158–149.
  • 47
    Peterson ME, Melian C, Nichols R. Measurement of serum total thyroxine, triiodothyronine, free thyroxine, and thyrotropin concentrations for diagnosis of hypothyroidism in dogs. J Am Vet Med Assoc 1997;211:13961402.
  • 48
    Diaz-Espineira MM, Mol JA, van den Ingh TS, et al. Functional and morphological changes in the adenohypophysis of dogs with induced primary hypothyroidism: loss of TSH hypersecretion, hypersomatotropism, hypoprolactinemia, and pituitary enlargement with transdifferentiation. Domest Anim Endocrinol 2008;35:98111.
  • 49
    Daminet S, Ferguson DC. Influence of drugs on thyroid function in dogs. J Vet Intern Med 2003;17:463472.
  • 50
    Hasler A, Rohner K. Serious reactions after the TSH-stimulation test in the dog. Schweiz Arch Tierheilkd 1992;134:423427.
  • 51
    Panciera DL. Is it possible to diagnose canine hypothyroidism? J Small Anim Pract 1999;40:152157.
  • 52
    Sauvé F, Paradis M. Use of recombinant human thyroid-stimulating hormone for thyrotropin stimulation test in euthyroid dogs. Can Vet J 2000;41:215219.
  • 53
    Daminet S, Jeusette I, Duchateau L, et al. Evaluation of thyroid function in obese dogs and in dogs undergoing a weight loss protocol. J Vet Med A Physiol Pathol Clin Med 2003;50:213218.
  • 54
    Boretti FS, Sieber-Ruckstuhl NS, Willi B, et al. Comparison of the biological activity of recombinant human thyroid-stimulating hormone with bovine thyroid-stimulating hormone and evaluation of recombinant human thyroid-stimulating hormone in healthy dogs of different breeds. Am J Vet Res 2006;67:11691172.
  • 55
    Boretti FS, Sieber-Ruckstuhl NS, Favrot C, et al. Evaluation of recombinant human thyroid-stimulating hormone to test thyroid function in dogs suspected of having hypothyroidism. Am J Vet Res 2006;67:20122016.
  • 56
    Daminet S, Fifle L, Paradis M, et al. Use of recombinant human thyroid-stimulating hormone for thyrotropin stimulation test in healthy, hypothyroid and euthyroid sick dogs. Can Vet J 2007;48:12731279.
  • 57
    Boretti FS, Sieber-Ruckstuhl NS, Wenger-Riggenbach B, et al. Comparison of 2 doses of recombinant human thyrotropin for thyroid function testing in healthy and suspected hypothyroid dogs. J Vet Intern Med 2009;23:856861.
  • 58
    Diaz Espineira MM, Mol JA, Peeters ME, et al. Assessment of thyroid function in dogs with low plasma thyroxine concentration. J Vet Intern Med 2007;21:2532.
  • 59
    Greco DS, Feldman EC, Peterson ME, et al. Congenital hypothyroid dwarfism in a family of Giant Schnauzers. J Vet Intern Med 1991;5:5765.
  • 60
    Robinson WF, Shaw SE, Stanley B, et al. Congenital hypothyroidism in Scottish Deerhound puppies. Aust Vet J 1988;65:386389.
  • 61
    De Roover K, Duchateau L, Carmichael N, et al. Effect of storage of reconstituted recombinant human thyroid-stimulating hormone (rhTSH) on thyroid-stimulating hormone (TSH) response testing in euthyroid dogs. J Vet Intern Med 2006;20:812817.
  • 62
    Scott-Moncrieff JC. Hypothyroidism. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine, 7th ed. St. Louis, MO: Saunders Elsevier; 2010:17511760.
  • 63
    Turrel JM, McEntee MC, Burke BP, et al. Sodium iodide I131 treatment of dogs with nonresectable thyroid tumors: 39 cases (1990-2003). J Am Vet Med Assoc 2006;229:542548.
  • 64
    Worth AJ, Zuber RM, Hocking M. Radioiodide (131I) therapy for the treatment of canine thyroid carcinoma. Aust Vet J 2005;83:208214.
  • 65
    Campos M, Peremans K, Duchateau L, et al. Effect of recombinant human TSH on the uptake of radioactive iodine ((123)I) by the thyroid gland in healthy Beagles. Domest Anim Endocrinol 2010;39:215221.
  • 66
    Rijnberk A. Iodine Metabolism and Thyroid Disease in the Dog. PhD thesis. Utrecht, The Netherlands: University of Utrecht;1971.
  • 67
    Kaneko JJ, Tyler WS, Wind A, et al. Clinical applications of the thyroidal I131 uptake test in the dog. J Am Vet Med Assoc 1959;135:516520.
  • 68
    Michaelson SM, Quinlan W Jr, Casarett GW, et al. Radiation-induced thyroid dysfunction in the dog. Radiat Res 1967;30:3847.
  • 69
    Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001;86:51485151.
  • 70
    Nielsen VE, Bonnema SJ, Hegedus L. Effects of 0.9 mg recombinant human thyrotropin on thyroid size and function in normal subjects: A randomized, double-blind, cross-over trial. J Clin Endocrinol Metab 2004;89:22422247.
  • 71
    Pena S, Arum S, Cross M, et al. 123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers. J Clin Endocrinol Metab 2006;91:506510.
  • 72
    Vargas GE, Uy H, Bazan C, et al. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 1999;84:38673871.
  • 73
    Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: A comprehensive review. Endocr Relat Cancer 2005;12:4964.
  • 74
    Campos M, Saunders JH, Duchateau L, et al. Short-term effect of recombinant human thyroid-stimulating hormone on thyroid volume and echogenicity in healthy Beagles. Vet Radiol Ultrasound 2010;51:331334.
  • 75
    Stegeman JR, Graham PA, Hauptman JG. Use of recombinant human thyroid-stimulating hormone for thyrotropin-stimulation testing of euthyroid cats. Am J Vet Res 2003;64:149152.
  • 76
    van Hoek I, Peremans K, Vandermeulen E, et al. Effect of recombinant human thyroid stimulating hormone on serum thyroxin and thyroid scintigraphy in euthyroid cats. J Feline Med Surg 2009;11:309314.
  • 77
    Edinboro CH, Scott-Moncrieff JC, Janovitz E, et al. Epidemiologic study of relationships between consumption of commercial canned food and risk of hyperthyroidism in cats. J Am Vet Med Assoc 2004;224:879886.
  • 78
    Peterson ME, Graves TK, Cavanagh I. Serum thyroid hormone concentrations fluctuate in cats with hyperthyroidism. J Vet Intern Med 1987;1:142146.
  • 79
    Peterson ME, Melian C, Nichols R. Measurement of serum concentrations of free thyroxine, total thyroxine, and total triiodothyronine in cats with hyperthyroidism and cats with nonthyroidal disease. J Am Vet Med Assoc 2001;218:529536.
  • 80
    Mooney CT, Little CJ, Macrae AW. Effect of illness not associated with the thyroid gland on serum total and free thyroxine concentrations in cats. J Am Vet Med Assoc 1996;208:20042008.
  • 81
    Wakeling J, Moore K, Elliott J, et al. Diagnosis of hyperthyroidism in cats with mild chronic kidney disease. J Small Anim Pract 2008;49:287294.
  • 82
    Mooney CT. Hyperthyroidism. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine, 7th ed. St. Louis, MO: Saunders Elsevier; 2010:17611779.
  • 83
    Peterson ME, Kintzer PP, Cavanagh PG, et al. Feline hyperthyroidism: Pretreatment clinical and laboratory evaluation of 131 cases. J Am Vet Med Assoc 1983;183:103110.
  • 84
    Mooney CT, Thoday KL, Doxey DL. Serum thyroxine and triiodothyronine responses of hyperthyroid cats to thyrotropin. Am J Vet Res 1996;57:987991.
  • 85
    Burman KD, Cooper DS. Hyperthyroidism due to Graves' disease, toxic nodules and toxic multinodular goiter. In: Cooper DS, ed. Medical Management of Thyroid Disease, 2nd ed. New York: Informa Healthcare; 2008:39100.
  • 86
    Peterson ME. Radioiodine treatment of hyperthyroidism. Clin Tech Small Anim Pract 2006;21:3439.
  • 87
    Harding LK, Thomson WH. Cats and hyperthyroidism. Nucl Med Commun 1997;18:11131114.
  • 88
    Chalmers HJ, Scrivani PV, Dykes NL, et al. Identifying removable radioactivity on the surface of cats during the first week after treatment with iodine 131. Vet Radiol Ultrasound 2006;47:507509.
  • 89
    Feeney DA, Jessen CR, Weichselbaum RC, et al. Relationship between orally administered dose, surface emission rate for gamma radiation, and urine radioactivity in radioiodine-treated hyperthyroid cats. Am J Vet Res 2003;64:12421247.
  • 90
    Weichselbaum RC, Feeney DA, Jessen CR. Evaluation of relationships between pretreatment patient variables and duration of isolation for radioiodine-treated hyperthyroid cats. Am J Vet Res 2003;64:425427.
  • 91
    van Hoek I, Daminet S, Vandermeulen E, et al. Recombinant human thyrotropin administration enhances thyroid uptake of radioactive iodine in hyperthyroid cats. J Vet Intern Med 2008;22:13401344.
  • 92
    Daminet S. Feline hypothyroidism. In: Mooney CT, Peterson ME, eds. BSAVA Manual of Canine and Feline Endocrinology 4th ed. Quedgeley, Gloucester: British Small Animal Veterinary Association; 2012:111115.
  • 93
    Quante S, Fracassi F, Gorgas D, et al. Congenital hypothyroidism in a kitten resulting in decreased IGF-I concentration and abnormal liver function tests. J Feline Med Surg 2010;12:487490.
  • 94
    Peterson ME, Becker DV. Radioiodine treatment of 524 cats with hyperthyroidism. J Am Vet Med Assoc 1995;207:14221428.
  • 95
    Chun R, Garrett LD, Sargeant J, et al. Predictors of response to radioiodine therapy in hyperthyroid cats. Vet Radiol Ultrasound 2002;43:587591.
  • 96
    Nykamp SG, Dykes NL, Zarfoss MK, et al. Association of the risk of development of hypothyroidism after iodine 131 treatment with the pretreatment pattern of sodium pertechnetate Tc 99m uptake in the thyroid gland in cats with hyperthyroidism: 165 cases (1990-2002). J Am Vet Med Assoc 2005;226:16711675.
  • 97
    van Hoek I, Vandermeulen E, Peremans K, et al. Thyroid stimulation with recombinant human thyrotropin in healthy cats, cats with non-thyroidal illness and in cats with low serum thyroxin and azotaemia after treatment of hyperthyroidism. J Feline Med Surg 2010;12:117121.
  • 98
    Williams TL, Elliott J, Syme HM. Association of iatrogenic hypothyroidism with azotemia and reduced survival time in cats treated for hyperthyroidism. J Vet Intern Med 2010;24:10861092.
  • 99
    Peterson ME, Gamble DA. Effect of nonthyroidal illness on serum thyroxine concentrations in cats: 494 cases (1988). J Am Vet Med Assoc 1990;197:12031208.
  • 100
    Spitzweg C, Morris JC. Sodium iodide symporter (NIS) and thyroid. Hormones (Athens) 2002;1:2234.
  • 101
    Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: Prospects and novel uses. Thyroid 2008;18:509516.
  • 102
    Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888896.
  • 103
    Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994;78:188196.
  • 104
    Lippi F, Capezzone M, Angelini F, et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001;144:511.
  • 105
    Nielsen VE, Bonnema SJ, Jorgensen HB, et al. Stimulation with 0,3 mg recombinant human thyrotropin (rhTSH) increases the effect of 131I therapy in patients with nontoxic nodular goiter. A prospective, randomized, double-blind trial–secondary publication. Ugeskr Laeger 2006;168:40984101.
  • 106
    Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:9195.
  • 107
    Saab G, Driedger AA, Pavlosky W, et al. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid 2006;16:267272.
  • 108
    Leboulleux S, Schroeder PR, Busaidy NL, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009;94:13101316.
  • 109
    Fugazzola L, Persani L, Mannavola D, et al. Recombinant human TSH testing is a valuable tool for differential diagnosis of congenital hypothyroidism during L-thyroxine replacement. Clin Endocrinol (Oxf) 2003;59:230236.
  • 110
    Fugazzola L, Persani L, Vannucchi G, et al. Thyroid scintigraphy and perchlorate test after recombinant human TSH: A new tool for the differential diagnosis of congenital hypothyroidism during infancy. Eur J Nucl Med Mol Imaging 2007;34:14981503.
  • 111
    Tiosano D, Even L, Shen Orr Z, et al. Recombinant thyrotropin in the diagnosis of congenital hypothyroidism. J Clin Endocrinol Metab 2007;92:14341437.
  • 112
    Novack DV. TSH, the bone suppressing hormone. Cell 2003;115:129130.
  • 113
    Antunes TT, Gagnon A, Chen B, et al. Interleukin-6 release from human abdominal adipose cells is regulated by thyroid-stimulating hormone: Effect of adipocyte differentiation and anatomic depot. Am J Physiol Endocrinol Metab 2006;290:E1140E1144.
  • 114
    Harbour DV, Kruger TE, Coppenhaver D, et al. Differential expression and regulation of thyrotropin (TSH) in T cell lines. Mol Cell Endocrinol 1989;64:229241.